AU2003215524A1 - Pharmaceutical compositions comprising mannose binding lectin - Google Patents

Pharmaceutical compositions comprising mannose binding lectin

Info

Publication number
AU2003215524A1
AU2003215524A1 AU2003215524A AU2003215524A AU2003215524A1 AU 2003215524 A1 AU2003215524 A1 AU 2003215524A1 AU 2003215524 A AU2003215524 A AU 2003215524A AU 2003215524 A AU2003215524 A AU 2003215524A AU 2003215524 A1 AU2003215524 A1 AU 2003215524A1
Authority
AU
Australia
Prior art keywords
mbl
pharmaceutical compositions
binding lectin
compositions
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003215524A
Other languages
English (en)
Inventor
Leif Kongerslev
Jesper Lund Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NatImmune AS
Original Assignee
NatImmune AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NatImmune AS filed Critical NatImmune AS
Publication of AU2003215524A1 publication Critical patent/AU2003215524A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003215524A 2002-03-15 2003-03-14 Pharmaceutical compositions comprising mannose binding lectin Abandoned AU2003215524A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200414 2002-03-15
DKPA200200414 2002-03-15
PCT/DK2003/000179 WO2003077937A1 (en) 2002-03-15 2003-03-14 Pharmaceutical compositions comprising mannose binding lectin

Publications (1)

Publication Number Publication Date
AU2003215524A1 true AU2003215524A1 (en) 2003-09-29

Family

ID=27763313

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003215524A Abandoned AU2003215524A1 (en) 2002-03-15 2003-03-14 Pharmaceutical compositions comprising mannose binding lectin

Country Status (11)

Country Link
US (1) US7462596B2 (https=)
EP (1) EP1344533B1 (https=)
JP (1) JP2005526084A (https=)
CN (1) CN1652813A (https=)
AT (1) ATE337014T1 (https=)
AU (1) AU2003215524A1 (https=)
DE (1) DE60307701T2 (https=)
DK (1) DK1344533T3 (https=)
ES (1) ES2271515T3 (https=)
PT (1) PT1344533E (https=)
WO (1) WO2003077937A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
ATE541582T1 (de) 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
TR201906789T4 (tr) 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
US7335633B2 (en) * 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
EP1618887A1 (en) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Clearance of polyols from the body
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
JP4744533B2 (ja) * 2004-12-30 2011-08-10 ドゥビエル カンパニー リミテッド 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法
WO2006108417A2 (en) * 2005-04-11 2006-10-19 Natimmune A/S Mannan-binding lectin (mbl) in the treatment of immunocompromised conditions associated with cancer
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
US20090304686A1 (en) * 2006-03-08 2009-12-10 Universotair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen
EP3050566B1 (en) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US20120282285A1 (en) 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
CN102947341B (zh) 2010-01-19 2018-07-06 哈佛大学校长及研究员协会 用于病原体检测和治疗的工程化调理素
EP2547205B1 (en) 2010-03-19 2024-03-20 1Globe Biomedical Co., Ltd. Novel methods for targeting cancer stem cells
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
CN104284984B (zh) 2012-02-29 2017-10-13 哈佛大学校长及研究员协会 抗生素药敏性的快速测试
KR102339315B1 (ko) * 2012-06-18 2021-12-15 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT
EP2983790A2 (en) 2013-04-09 2016-02-17 Boston Biomedical, Inc. Methods for treating cancer
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3083658B1 (en) 2013-12-18 2019-05-08 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
CN110755601B (zh) * 2019-10-31 2023-06-23 云南康洲生物科技有限公司 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
WO2023055250A1 (en) * 2021-10-01 2023-04-06 University Of Belgrade Carbohydrate binding polypeptide of savalia savaglia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509089A (en) * 1998-06-10 2002-10-25 Statens Seruminstitut Affinity chromatography purification for production of mannan-binding lectin
US6429192B1 (en) * 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
EP1181038B1 (en) * 1999-05-14 2004-04-14 Steffen Thiel Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin

Also Published As

Publication number Publication date
US7462596B2 (en) 2008-12-09
EP1344533B1 (en) 2006-08-23
WO2003077937A1 (en) 2003-09-25
ATE337014T1 (de) 2006-09-15
ES2271515T3 (es) 2007-04-16
CN1652813A (zh) 2005-08-10
DE60307701T2 (de) 2007-10-11
DK1344533T3 (da) 2007-01-08
DE60307701D1 (de) 2006-10-05
JP2005526084A (ja) 2005-09-02
PT1344533E (pt) 2007-01-31
EP1344533A1 (en) 2003-09-17
US20040006009A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
AU2003215524A1 (en) Pharmaceutical compositions comprising mannose binding lectin
IL203923A (en) Benzamide compounds, pharmaceutical compositions comprising them, use thereof in the preparation of medicaments and as medicaments and processes for the preparation of such compounds
HK81397A (en) Pharmaceutical compositions containing benzenesulphonamides
HUP0401241A3 (en) Novel cyclohexyl sulphones, process for their preparation and pharmaceutical compositions containing them
HUP0303148A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
CA2534798A1 (en) Thiazole derivatives as cannabinoid receptor modulators
HUP0402225A3 (en) Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
CA2338600A1 (en) Novel thiazolopyrimidine compounds
HUP0103063A3 (en) Novel 2h-pyridazin-3-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them
IL171914A0 (en) Variants of il-18bp, their preparation and pharmaceutical compositions containing them
AU2003202719A1 (en) Novel antibacterial compounds:process for their preparation and pharmaceutical compositions containing them.
AU2002348829A1 (en) Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2003020963A3 (en) Proteins in type 2 diabetes
PL346143A1 (en) Tan-1057 derivatives
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
WO2003050067A3 (fr) Analogues de la vitamine d
HUP0401082A3 (en) Substituted 4-aminocyclohexanols, process for their preparation and pharmaceutical compositions containing them
WO2000072833A3 (de) Pharmazeutische zubereitungen zur hemmung von spimgomyelinase
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
WO2002070537A3 (en) Fusidic acid derivatives
HUP0401906A3 (en) Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase